Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention (2025)
Chapter: Appendix B: Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications
Visit
NAP.edu/10766
to get more information about this book, to buy it in print, or to
download it as a free PDF.
Previous Chapter:
Appendix A: Committee Member and Staff Biographies
Appendix B
Next Chapter: Appendix C: Westat Key Informant Interviews Findings Report
Suggested Citation:
"Appendix B: Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications." National Academies of Sciences, Engineering, and Medicine. 2025. Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention. Washington, DC: The National Academies Press.
doi: 10.17226/29240.
Appendix B
Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention’s COVID-19 Vaccine Safety Research and Communications
FIRST INFORMATION GATHERING SESSION
June 24, 2024
Washington, DC
| 1:00 | Welcome and Introductions; Conduct of the Open Session |
| Jane Henney, M.D., Committee Chair | |
| 1:00–2:30 | Presentation by CDC Immunization Safety Office on the Statement of Task |
| John Su, M.D., Acting Director, Immunization Safety Office (virtual) | |
| Q&A with Committee | |
| John Su, M.D., Acting Director, Immunization Safety Office (virtual) | |
| 2:30 | Closing Comments, OPEN SESSION ENDS |
| Jane Henney, M.D., Committee Chair |
Suggested Citation:
"Appendix B: Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications." National Academies of Sciences, Engineering, and Medicine. 2025. Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention. Washington, DC: The National Academies Press.
doi: 10.17226/29240.
SECOND INFORMATION GATHERING SESSION
August 7, 2024
Washington, DC
| 2:00 | Welcome and Introductions; Conduct of the Open Session |
| Jane Henney, M.D., Committee Chair | |
| 2:00–4:00 | CDC Response to Vaccines Safety Needs for the U.S. COVID-19 Vaccination Program: An Overview of Vaccine Safety Systems |
| Julianne Gee, MPH, Senior Advisor, ISO, CDC (virtual) | |
| 4:00 | Closing Remarks, OPEN SESSION ENDS |
| Jane Henney, M.D., Committee Chair |
THIRD INFORMATION GATHERING SESSION
October 11, 2024
Virtual
| 11:00-11:10 | Welcome and Introductions; Conduct of the Public Comment Session |
| Jane Henney, M.D., Committee Chair | |
| 11:00–1:00 | The Committee to Review the Centers for Disease Control and Prevention’s COVID-19 Vaccine Safety Research and Communications Public Comment Session |
| 1:00 | Closing Remarks, OPEN SESSION ENDS |
| Jane Henney, M.D., Committee Chair |
FOURTH INFORMATION GATHERING SESSION
January 10, 2025
Washington, DC
| 10:30 | Welcome and Introductions; Conduct of the Public Comment Session |
| Jane Henney, M.D., Committee Chair |
Suggested Citation:
"Appendix B: Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications." National Academies of Sciences, Engineering, and Medicine. 2025. Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention. Washington, DC: The National Academies Press.
doi: 10.17226/29240.
| 10:30–12:30 | Presentation on CDC COVID-19 Vaccine Safety Risk Communications |
| Daniel Jernigan, M.D., MPH, Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) (virtual) | |
| 12:30 | Closing Remarks, OPEN SESSION ENDS |
| Jane Henney, M.D., Committee Chair |
FIFTH INFORMATION GATHERING SESSION
February 25, 2025
Washington, DC
| 1:00 | Welcome and Introductions; Conduct of the Public Comment Session |
| Jane Henney, M.D., Committee Chair | |
| 1:00–2:30 | Presentation on Challenges and Opportunities for Research and Communication About Vaccine Safety |
| Reed Tuckson, M.D., Tuckson Health Connections, LLC, Black Coalition Against COVID | |
| Lisa Fitzgerald, M.D., MPH, MPA, Grapevine Health (Unable to attend) | |
| Malia Jones, Ph.D., University of Wisconsin, Madison | |
| Scott Razan, M.D., MPA, M.A., CUNY Graduate School of Public Health & Health Policy | |
| 2:30 | Closing Remarks, OPEN SESSION ENDS |
| Jane Henney, M.D., Committee Chair |
Suggested Citation:
"Appendix B: Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications." National Academies of Sciences, Engineering, and Medicine. 2025. Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention. Washington, DC: The National Academies Press.
doi: 10.17226/29240.
This page intentionally left blank.
Suggested Citation:
"Appendix B: Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications." National Academies of Sciences, Engineering, and Medicine. 2025. Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention. Washington, DC: The National Academies Press.
doi: 10.17226/29240.
Suggested Citation:
"Appendix B: Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications." National Academies of Sciences, Engineering, and Medicine. 2025. Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention. Washington, DC: The National Academies Press.
doi: 10.17226/29240.
Suggested Citation:
"Appendix B: Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications." National Academies of Sciences, Engineering, and Medicine. 2025. Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention. Washington, DC: The National Academies Press.
doi: 10.17226/29240.
Suggested Citation:
"Appendix B: Public Meeting Agendas for the Committee to Review the Center for Disease Control and Prevention's COVID-19 Vaccine Safety Research and Communications." National Academies of Sciences, Engineering, and Medicine. 2025. Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention. Washington, DC: The National Academies Press.
doi: 10.17226/29240.
Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.